Titolo progetto: AIRC 2021 - Reverse the silencing: Targeting the MEF2-class IIa HDACs axis in leiomyosarcomas.

Programma di finanziamento: Bando AIRC 2021

Responsabile scientifico: Prof. Claudio Brancolini

Collaboratori: Prof.ssa Teresa Gagliano

Ruolo del DAME: proponente unico

Descrizione generale:

The proposal aims to extend, our initial discovery about a role of MEF2D and HDAC9 in sustaining the aggressiveness of LMS, and to clarify the role of this epigenetic circuit in the regulation of key regulative elements of the genome such as the super-enhancers, Goals are to understand the alterations of higher-order chromatin organization in LMS and their dependence on the MEF2-HDAC axis, as well as to clarify the implications in the metastatic process and in the immune escape. In parallel, the proposal aims to propose new therapeutic approaches to reverse the epigenetic silencing imposed in LMS.

Date inizio e fine progetto:02.01.2022 – 01.04.2027

Budget totale del progetto: 476.300,00 €